Nausea on a GLP-1: the label rates, when it peaks, and a management routine that clinicians actually recommend

Nausea is the reason more people stop a GLP-1 than any other, and the reason more people stay on a dose lower than their prescriber intended. It is also the most predictable adverse effect there is: the labels tell you how common it is, roughly when it comes, and what the one dosing lever is. This guide puts the numbers first, then the routine.

The numbers on the labels

The Wegovy label's adverse reaction table pools the placebo-controlled weight-management trials in adults (STEP 1, 2 and 3): nausea in 44 percent of people on semaglutide 2.4 mg versus 16 percent on placebo; vomiting 24 versus 6; diarrhoea 30 versus 16; constipation 24 versus 11; abdominal pain 20 versus 10; dyspepsia 9 versus 3; eructation (belching) 7 versus under 1; reflux 5 versus 3.

The Zepbound label pools SURMOUNT-1 and SURMOUNT-2 by maintenance dose: nausea in 25, 29 and 28 percent at 5, 10 and 15 mg versus 8 percent on placebo; vomiting 8, 11 and 13 versus 2; diarrhoea 19, 21 and 23 versus 8; constipation 17, 14 and 11 versus 5; dyspepsia 9, 9 and 10 versus 4; eructation 4, 5 and 5 versus 1; reflux 4, 4 and 5 versus 2.

Two cautions when comparing them. Different trials, different populations and different dose-escalation schedules; the labels are not a head-to-head. And a percentage of people reporting nausea at some point over 68 or 72 weeks says nothing about how bad it was or how long it lasted for any one of them. Both labels describe the GI reactions as mostly mild to moderate and as occurring mostly during dose escalation.

When it comes and why

Both drugs slow gastric emptying and act on appetite centres in the brain; both effects are largest when a new dose level is reached and settle over the following weeks. The labels' escalation schedules exist for exactly this reason: Wegovy's label says to follow the escalation "to reduce the risk of gastrointestinal adverse reactions", and Zepbound's says the same of its 4-week steps. The practical pattern most people describe, and the clinical recommendations papers confirm, is a few worse days after each step-up, easing over one to three weeks, then a new step.

Nausea that arrives out of pattern, weeks into a stable dose, or that is accompanied by pain, is a different problem and belongs in the warning-signs section below.

The dosing lever on the label

This is the part people are not told. The Wegovy label says: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks." It also says that if the 2.4 mg maintenance dose is not tolerated, the dose can be decreased to 1.7 mg once weekly, with re-escalation considered later. The Zepbound label says: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." The maintenance doses are 5, 10 and 15 mg; the label does not require reaching 15.

In plain terms, staying longer on a step, or settling at a lower step, is on the label. It is not failure and it is not off-protocol. The dose escalation guide covers how to raise this with a prescriber. Never adjust a dose yourself, and never split or skip a pen dose to "ease in"; the pens are fixed-dose devices and the label rules do not cover partial doses.

The management routine

The following comes from two published clinical-practice papers written by obesity and diabetes clinicians for other clinicians: Wharton and colleagues (Postgrad Med 2022, PubMed 34775881) and the Spanish multidisciplinary consensus by Gorgojo-Martinez and colleagues (J Clin Med 2022, PubMed 36614945). It is general practice, not label text.

Eat smaller amounts, more slowly, and stop at the first sign of fullness. A slower stomach holds food longer; the volume that used to be a normal meal is now too much. Both papers put portion size first.

Reduce fat and heavily spiced or fried food, especially in escalation weeks. Fat further slows gastric emptying. Plain, lower-fat meals empty faster and provoke less nausea.

Do not lie down straight after eating. Reflux is on both labels; an upright hour after meals reduces it.

Drink fluids between meals rather than with them, and keep drinking; the hydration guide explains why volume depletion is the label's real concern.

Avoid alcohol in escalation weeks. It irritates the stomach and adds a cause of vomiting; see the alcohol guide.

Bland options for bad days. Both papers list the usual: dry toast, crackers, rice, bananas, clear soups, ginger or peppermint tea. None of these is evidence-based in the trial sense; they are what clinicians recommend because they are low-fat, low-volume and tolerated.

Time the injection. Some people find injecting in the evening puts the worst hours in their sleep. The labels allow injection at any time of day, so this is a free variable. Changing the day of the week is also permitted within the label limits (72 hours between doses for Zepbound and Mounjaro, 48 for Wegovy and Ozempic).

Ask about an antiemetic for escalation weeks. Both papers discuss short courses of standard anti-nausea medication as an option a prescriber may choose. The labels neither recommend nor forbid it. It is a prescription decision.

Ask about staying on the step. If a step is rough, the label lever above exists. Raise it before the next scheduled increase, not after.

What does not help

Skipping meals entirely: an empty stomach makes nausea worse for many people and increases the chance of hypoglycaemia in anyone on insulin or a sulfonylurea. Very large volumes of water at once. Pushing through severe vomiting to stay on schedule; a dose taken and vomited within the hour has still been absorbed (it is injected, not swallowed), so vomiting after an injection does not mean the dose was lost and is never a reason to inject again.

Warning signs: this is not ordinary nausea

Each of these is a label warning, and each needs a call the same day or urgent care.

Severe, persistent abdominal pain, sometimes radiating to the back, with or without vomiting. This is the label's description of acute pancreatitis. The labels say to discontinue the drug if pancreatitis is suspected and not to restart it if confirmed.

Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools. The gallbladder warning. The Wegovy label reports cholelithiasis in 1.6 percent of treated adults versus 0.7 percent on placebo and cholecystitis in 0.6 versus 0.2; the Zepbound label reports 1.1 versus 1.0 and 0.7 versus 0.2 respectively. The labels say substantial or rapid weight loss itself raises gallstone risk.

Vomiting or diarrhoea so persistent you cannot keep fluids down, passing little urine, dizziness on standing. The volume-depletion and acute kidney injury warning, discussed in the hydration guide.

Vomiting that is severe or that persists well beyond the escalation period. The labels' severe gastrointestinal adverse reactions section notes that the drugs are not recommended in people with severe gastroparesis and that severe GI reactions have been reported; new, severe or persistent symptoms are a reason to be assessed, not managed at home.

Nausea with a planned procedure. Active GI symptoms are a named risk factor in the perioperative guidance; see the surgery guide.

Compounded products

Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with the brand products whose labels supply the rates above; there is no equivalent adverse-event table for any compounded product. Two additional causes of nausea exist with vials that do not exist with pens: a dosing error from a units-versus-millilitres mistake or a changed concentration, and a schedule that does not follow the label escalation. The FDA's page on its concerns with compounded GLP-1s describes both. If nausea arrived with a new vial, check the concentration and the volume before anything else, using the dose unit converter. FormBlends' semaglutide and tirzepatide pages describe how its pharmacies label their vials.